Literature DB >> 26757038

Prognostic Significance of Mild Cognitive Impairment Subtypes for Dementia and Mortality: Data from the NEDICES Cohort.

Félix Bermejo-Pareja1,2, Israel Contador3, Rocío Trincado2, David Lora4, Álvaro Sánchez-Ferro5,6, Alex J Mitchell7, Elina Boycheva4, Alejandro Herrero8, Jesús Hernández-Gallego2,8,9, Sara Llamas4, Alberto Villarejo Galende2,8, Julián Benito-León2,8.   

Abstract

BACKGROUND: The predictive value of diverse subtypes of mild cognitive impairment (MCI) for dementia and death is highly variable.
OBJECTIVE: To compare the predictive value of several MCI subtypes in progression to dementia and/or mortality in the NEDICES (Neurological Disorders in Central Spain) elderly cohort.
METHODS: Retrospect algorithmic MCI subgroups were established in a non-dementia baseline NEDICES cohort using Spanish adaptations of the original Mini-Mental State Examination (MMSE-37) and Pfeffer's Functional Activities Questionnaire (Pfeffer-11). The presence of MCI was defined according two cognitive criteria: using two cut-offs points on the total MMSE-37 score. Five cognitive domains were used to establish the MCI subtypes. Functional capacity (Pfeffer-11) was preserved or minimally impaired in all MCI participants. The incident dementia diagnoses were established by specialists and the mortality data obtained from Spanish official registries.
RESULTS: 3,411 participants without dementia were assessed in 1994-5. The baseline prevalence of MCI varied according to the MCI definition (4.3%-31.8%). The follow-up was a mean of 3.2 years (1997-8). The dementia incidence varied between 14.9 and 71.8 per 1,000/person-years. The dementia conversion rate was increased in almost all MCI subgroups (p >  0.01), and mortality rate was raised only in four MCI subtypes. The amnestic-multi-domain MCI (aMd-MCI) had the best dementia predictive accuracy (highest positive likelihood ratio and highest clinical utility when negative).
CONCLUSIONS: Those with aMd-MCI were at greatest risk of progression to dementia, as in other surveys and might be explored with increased attention in MCI research and in dementia preventive trials.

Entities:  

Keywords:  Amnesic multidomain MCI; MCI mortality; MCI subtypes; MMSE-37; NEDICES; Pfeffer’s FAQ; dementia; dementia conversion

Mesh:

Year:  2016        PMID: 26757038     DOI: 10.3233/JAD-150625

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  9 in total

1.  Combining Gait Speed and Recall Memory to Predict Survival in Late Life: Population-Based Study.

Authors:  Alessandra Marengoni; Stefania Bandinelli; Elisa Maietti; Jack Guralnik; Giovanni Zuliani; Luigi Ferrucci; Stefano Volpato
Journal:  J Am Geriatr Soc       Date:  2016-12-28       Impact factor: 5.562

2.  Life expectancy with and without dementia in persons with mild cognitive impairment in the community.

Authors:  Sanne S Mooldijk; Amber Yaqub; Frank J Wolters; Silvan Licher; Peter J Koudstaal; M Kamran Ikram; M Arfan Ikram
Journal:  J Am Geriatr Soc       Date:  2021-10-18       Impact factor: 7.538

3.  Mild cognitive impairment: narrative review of taxonomies and systematic review of their prediction of incident Alzheimer's disease dementia.

Authors:  Nicholas I Bradfield; David Ames
Journal:  BJPsych Bull       Date:  2020-04

4.  Autonomic function in amnestic and non-amnestic mild cognitive impairment: spectral heart rate variability analysis provides evidence for a brain-heart axis.

Authors:  Paola Nicolini; Daniela Mari; Carlo Abbate; Silvia Inglese; Laura Bertagnoli; Emanuele Tomasini; Paolo D Rossi; Federico Lombardi
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

5.  Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment.

Authors:  Zachary A Marcum; Jordana B Cohen; Chong Zhang; Catherine G Derington; Tom H Greene; Lama Ghazi; Jennifer S Herrick; Jordan B King; Alfred K Cheung; Nick Bryan; Mark A Supiano; Joshua A Sonnen; William S Weintraub; Jeff Williamson; Nicholas M Pajewski; Adam P Bress
Journal:  JAMA Netw Open       Date:  2022-01-04

6.  Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway.

Authors:  Bjørn Heine Strand; Anne-Brita Knapskog; Karin Persson; Trine Holt Edwin; Rachel Amland; Marit Mjørud; Espen Bjertness; Knut Engedal; Geir Selbæk
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

7.  Distinguishing mild cognitive impairment from healthy aging and Alzheimer's Disease: The contribution of the INECO Frontal Screening (IFS).

Authors:  Helena S Moreira; Ana Sofia Costa; Álvaro Machado; São Luís Castro; César F Lima; Selene G Vicente
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240

8.  Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.

Authors:  Félix Bermejo-Pareja; Teodoro Del Ser; Meritxell Valentí; Mónica de la Fuente; Fernando Bartolome; Eva Carro
Journal:  Alzheimers Dement       Date:  2020-06-16       Impact factor: 21.566

9.  Mild cognitive impairment, dementia and risk of mortality in essential tremor: A longitudinal prospective study of elders.

Authors:  Nikki Delgado; Daniella Iglesias Hernandez; Keith Radler; Edward D Huey; Stephanie Cosentino; Elan Louis
Journal:  J Neurol Sci       Date:  2021-07-02       Impact factor: 4.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.